U.S. Communications Stock News

If you are wondering whether Kinsale Capital Group at around US$345 per share looks like value or a value trap, the next sections break down what the current price might be implying. The stock has been volatile recently, with a 4.4% decline over the last 7 days, a 5.4% gain over 30 days, and returns of 12.1% decline year to date and 17.7% decline over the last year, set against 6.1% and 100.1% gains over 3 and 5 years respectively. Recent coverage around Kinsale Capital Group has focused on...

Agree Realty (ADC) has drawn fresh attention after reporting first quarter 2026 results with year over year growth in core FFO and AFFO per share, while also completing its largest acquisition volume since 2022. See our latest analysis for Agree Realty. Despite the recent flurry of capital raises and acquisitions, Agree Realty’s share price has been steady overall, with a 30 day share price return of 3.06% and a 90 day share price return of 5.56%. The 5 year total shareholder return of 34.45%...

Structure Therapeutics (GPCR) has drawn fresh attention after recent trading left the stock at US$45.49, while performance over the past 3 months and the past month contrasts sharply with a strong 1 year total return. See our latest analysis for Structure Therapeutics. The recent share price pullback, including a 3.25% one day share price decline and a 49.21% 90 day share price decline from a much stronger 1 year total shareholder return of 91.62%, suggests momentum has cooled as investors...

Why Eastern Bankshares (EBC) Is On Investors’ Radar Today Eastern Bankshares (EBC) is drawing attention after recent trading, with the share price closing at US$19.90 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Eastern Bankshares. Even after a 2.97% one day share price decline and 5.46% 7 day share price pullback to US$19.90, Eastern Bankshares still shows positive year to date share price momentum alongside strong multi year total...

World Kinect Corporation reported past first-quarter 2026 results with sales of US$9.69 billion, net income of US$26.2 million and a swing from loss to earnings per share, alongside completing a sizeable share repurchase under its 2024 buyback program. The quarter’s earnings and revenue were well ahead of analyst expectations, powered by strong Marine and Aviation performance and management’s ongoing portfolio simplification efforts despite continued weakness in the Land segment. We’ll now...

This article examines whether Iovance Biotherapeutics at US$3.44 offers value or mainly adds extra risk by breaking down what the current share price might be indicating. The stock has seen mixed returns, with a 10.9% decline over the last 7 days and a 2.0% decline over the past year, alongside a 36.5% gain year to date, a 39.0% decline over 3 years, and an 89.1% decline over 5 years. Recent attention on Iovance Biotherapeutics has put its share price movements in sharper focus for investors...

Biohaven has completed enrollment for its Phase 2 proof of concept trial evaluating obesity drug candidate taldefgrobep alfa. The study is assessing taldefgrobep alfa as a potential monotherapy and in combination with standard care. The company has indicated that topline results from the trial are expected later in the year. For investors tracking NYSE:BHVN, this update adds a fresh angle to a story often centered on its neurology pipeline. The stock closed at $9.88, with a 30 day return of...

StoneX Financial Europe GmbH has introduced a new Fat Filled Milk Powder contract as part of a broader OTC dairy derivatives suite developed with Expana. The launch extends StoneX Group's risk management offering for dairy clients in Europe, providing an additional tool for handling price volatility. The development highlights further product expansion beyond traditional financial instruments within StoneX Group's trading solutions. For investors watching StoneX Group (NasdaqGS:SNEX), the...

If you are wondering whether Crocs at around US$102 per share still offers value, it helps to step back and separate the recent excitement from what the business may be worth. The stock has had a mixed run, with a 3.4% decline over the last 7 days, a 28.6% gain over the last 30 days, a 17.7% return year to date, and a 4.8% return over the last year, set against weaker 3 year and 5 year returns of 17.3% and 2.2% respectively. These shifts have drawn more attention to how the market is...

Western Union (WU) opened 2026 with Q1 revenue of US$982.7 million and basic EPS of US$0.21, alongside net income of US$64.7 million, providing a clear snapshot of its recent financial performance. The company reported quarterly revenue of US$983.6 million and EPS of US$0.37 in Q1 2025, compared with US$982.7 million and EPS of US$0.21 in Q1 2026. Trailing twelve month EPS stands at US$1.37 on revenue of about US$4.0 billion, leaving investors focused on how the current margin profile shapes...

Wondering if Equinix at around US$1,108.76 is still a sensible entry or hold after its recent run? This guide focuses squarely on what you are paying versus what you might be getting. The stock has posted returns of 1.8% over the last 7 days, 15.1% over 30 days, 45.1% year to date and 35.4% over the past year, which can change how the market views both its potential and its risks. Recent attention on data center and digital infrastructure companies has kept Equinix in the conversation for...

Earlier this week, Tuya Smart unveiled an upgraded Hey Tuya platform at its 2026 Global Developer Summit, highlighting new AI capabilities, expanded smart home compatibility, and deeper integrations with services like Google Mail, Calendar, and Docs. The company also introduced AI-native hardware technologies and low-code tools such as Vibe Coding, which could meaningfully lower development barriers and broaden adoption of Tuya’s AIoT ecosystem. Next, we’ll examine how Hey Tuya’s expanded AI...

SES AI (SES) has just posted Q1 2026 results with revenue of US$6.7 million, a basic EPS loss of US$0.04, and a net income loss of US$12.1 million. This sets a clear tone for how much growth is currently coming at the expense of profitability. Over the past year, the company has seen quarterly revenue move from US$5.8 million in Q1 2025 to US$6.7 million in Q1 2026. Quarterly basic EPS losses have ranged between US$0.04 and US$0.11, underscoring a business still investing heavily to scale...

Wondering if West Pharmaceutical Services at around US$306 is priced for perfection or leaving something on the table for new investors? This article walks through what the current market price might be saying about value. The stock has delivered returns of 11.8% over the last 7 days, 25.8% over the last 30 days, 10.8% year to date and 43.2% over the last year. However, the 3 year and 5 year returns of negative 14.6% and negative 5.7% show a very different experience for anyone who held...

In the first quarter of 2026, Western Alliance Bancorporation reported net interest income of US$766.3 million, net income of US$182.1 million, diluted EPS of US$1.65, and net loan charge-offs of US$208.5 million, while completing a buyback of 1,600,000 shares for US$120.4 million. Alongside elevated fraud-related charge-offs, the bank delivered strong deposit growth, expanded its net interest margin, and held its CET1 capital ratio near 11%, highlighting balance-sheet resilience during a...

Why ARMOUR Residential REIT’s Q1 2026 Results Matter For Investors ARMOUR Residential REIT (ARR) drew investor focus after reporting a Q1 2026 net loss driven by mark to market pressure, while non GAAP distributable earnings fully covered its monthly dividend. See our latest analysis for ARMOUR Residential REIT. ARR’s recent earnings release, dividend affirmation and capital raises have arrived alongside a 12.02% 1 month share price return, while the 1 year total shareholder return of 30.98%...

Event context and recent share performance Aveanna Healthcare Holdings (AVAH) has drawn investor attention following recent share price swings. The stock has shown a 0.6% daily move, a small decline over the past week, and mixed returns over the past month and past three months. See our latest analysis for Aveanna Healthcare Holdings. At a share price of US$6.55, Aveanna’s recent 4.1% 1 month share price return contrasts with a 26.8% 3 month decline, while its 1 year total shareholder return...

In mid-April 2026, Spyre Therapeutics completed a US$403.00 million follow-on common stock offering at US$62.00 per share, shortly after reporting positive 12-week Phase 2 SKYLINE data for its ulcerative colitis candidate SPY001, which met its primary endpoint and showed a safety profile consistent with the a4ß7 class. The decision to expand the offering from a prior US$300.00 million filing and add Jefferies as co-lead underwriter underscores how the SPY001 data have become a central pillar...

Kaltura, Inc. recently expanded its AI-powered platform infrastructure to Europe, Asia-Pacific, and Canada while deepening product integrations and launching new agentic revenue engagement capabilities across major enterprise content systems. This push into compliant, region-specific AI infrastructure and unified conversational experiences could widen Kaltura’s addressable market among heavily regulated global enterprises. We’ll now examine how Kaltura’s regionally compliant AI rollout and...

Why Atomera’s latest Synopsys collaboration matters for investors Atomera (ATOM) is drawing fresh attention after expanding its long-running collaboration with Synopsys to support gallium nitride, or GaN, device modeling for radio frequency and power semiconductor applications. The new phase uses Synopsys’ Sentaurus TCAD tools alongside Atomera’s MSTcad to build GaN calibration workflows, marketing materials, and calibrated TCAD decks, giving semiconductor customers a framework to study MST’s...

In March 2026, National Energy Services Reunited announced US$300 million in multi-year cementing contract awards across Kuwait and North Africa, reinforcing its presence in key Middle East and North Africa oilfield service markets. This combination of fresh long-term work and recent recognition by UBS as a top emerging oil and gas opportunity underscores how contract visibility and external validation are shaping the company’s position in the sector. Against this backdrop of new multi-year...

LivaNova PLC recently reported that the Annals of Internal Medicine published 12‑month data from its OSPREY randomized controlled trial, showing sustained safety and clinically meaningful improvements in obstructive sleep apnea outcomes with the aura6000 proximal hypoglossal nerve stimulation system. The publication underscores that aura6000 delivered benefits across a diverse, higher-risk patient group, including those with higher BMI and predicted complete concentric collapse, potentially...

Last week, you might have seen that First Citizens BancShares, Inc. ( NASDAQ:FCNC.A ) released its first-quarter result...

W. R. Berkley’s first-quarter 2026 results showed revenue of US$3,690.33 million and net income of US$515.22 million, alongside continued buybacks and leadership changes in its oil, gas and environmental units. Beyond the headline growth in earnings per share, management’s emphasis on more selective underwriting and capital deployment signals a meaningful adjustment in how the insurer is approaching competition and risk. We’ll now explore how this shift toward selective underwriting and...